Neuroinflammation is a central pathological feature of Alzheimer's disease (AD), involving the chronic activation of microglia and astrocytes, release of pro-inflammatory cytokines, and activation of the complement system. Inflammatory biomarkers provide insight into disease mechanisms, progression, and may serve as therapeutic targets or biomarkers for clinical trials.
Unlike acute inflammation, the neuroinflammation in AD is characterized by a chronic, self-sustaining response that contributes to neuronal dysfunction and death. Understanding these inflammatory processes through biomarker measurement offers opportunities for early diagnosis, disease monitoring, and development of anti-inflammatory therapeutic approaches.
Microglia, the resident immune cells of the brain, undergo dramatic changes in AD:
- Morphological transformation: From ramified surveillant to amoeboid activated state
- Surface marker changes: Upregulation of CD68, Iba-1, TREM2
- Functional alterations: Changed phagocytic activity, cytokine secretion
TREM2 pathway: Triggering receptor expressed on myeloid cells 2 (TREM2) is critical for microglial function:
- Loss-of-function variants: Increase AD risk ~3-fold
- sTREM2: Soluble form released by activated microglia, detectable in CSF
- CSF levels: Correlate with disease stage and cognitive decline
Astrocytes also undergo reactive changes in AD, contributing to neuroinflammation:
- A1 phenotype: Neurotoxic reactive astrocytes producing complement components
- A2 phenotype: Potentially protective, producing neurotrophic factors
- Marker changes: GFAP upregulation, YKL-40 expression
The complement system is heavily involved in AD pathogenesis:
- C1q: Initiates complement; localizes to amyloid plaques
- C3: Central component; elevated in AD brain and CSF
- C5a: Pro-inflammatory anaphylatoxin; receptor blockage is neuroprotective in models
IL-6 is a pleiotropic cytokine with complex roles in AD:
- CSF levels: Elevated in AD vs controls
- Association: Correlates with cognitive decline rate
- Genetic link: IL-6 promoter variants affect AD risk
- Therapeutic target: IL-6 receptor antibodies under investigation
TNF-α is a key pro-inflammatory cytokine in AD:
- Levels: Elevated in AD CSF and blood
- Pathogenic role: Drives neurotoxicity through TNFR1
- Therapeutic approach: TNF inhibitors (etanercept) trialed in AD
- Genetic variants: TNF promoter polymorphisms affect risk
IL-1β has been implicated in AD pathogenesis for decades:
- Expression: Upregulated in AD brain, especially around plaques
- Genetic variants: IL-1B polymorphisms associated with increased risk
- Pathogenic mechanisms: Promotes tau phosphorylation, neurotoxicity
- Therapeutic challenge: Poor CSF penetration of IL-1 inhibitors
IL-18 is elevated in AD and correlates with disease severity:
- CSF levels: Higher in MCI and AD
- Association: With amyloid burden and cognitive decline
- Measurement challenges: Requires careful sample handling
sTREM2 reflects microglial activation in AD:
- Source: Proteolytic cleavage of membrane-bound TREM2
- CSF levels: Increased in early AD, peaks at MCI stage
- Clinical correlation: Associated with faster cognitive decline
- Utility: May indicate therapeutic target engagement
YKL-40 is a marker of astrocyte reactivity:
- CSF elevation: Seen in AD and other neurodegenerative diseases
- Prognostic value: Higher levels predict more rapid progression
- Specificity: Less specific than microglial markers
GFAP reflects astrocyte activation:
- Blood levels: Elevated in AD vs controls
- Dynamic range: Sensitive to disease stage
- Complementary: With microglial markers for comprehensive assessment
CXCL12 is involved in neuroinflammation and neurogenesis:
- Levels: Altered in AD brain and CSF
- Receptor (CXCR4): Expressed on neurons and glia
- Therapeutic potential: CXCR4 antagonists under investigation
¶ C3 and C3a
Complement C3 is a central inflammatory biomarker:
- CSF levels: Elevated in AD
- Source: Reactive astrocytes (A1 phenotype)
- Pathogenic role: Synapse elimination, opsonization
- Therapeutic target: C3 inhibitors in development
Inflammatory biomarkers contribute to AD diagnosis:
- Supportive evidence: Elevated inflammatory markers consistent with AD pathophysiology
- Differential diagnosis: Some patterns differentiate AD from other dementias
- Biomarker panels: Combination with core AD biomarkers improves accuracy
Longitudinal changes in inflammatory biomarkers:
- Progression markers: Higher baseline IL-6, sTREM2 predict faster decline
- Therapeutic monitoring: Anti-inflammatory treatment effects on biomarker levels
- Stage-dependent: Different biomarkers peak at different disease stages
Inflammatory biomarkers are used in clinical trials:
- Patient stratification: Enriching for patients with active neuroinflammation
- Mechanism of action: Demonstrating target engagement
- Outcome measures: Monitoring treatment effects on inflammation
¶ Biomarker Combinations and Panels
Combining multiple inflammatory biomarkers provides better information:
| Biomarker |
Source |
Primary Information |
| sTREM2 |
CSF |
Microglial activation |
| IL-6 |
CSF/Serum |
Systemic inflammation |
| YKL-40 |
CSF |
Astrocyte reactivity |
| C3 |
CSF |
Complement activation |
| GFAP |
Plasma |
Astrocyte activation |
Inflammatory markers complement core AT(N) biomarkers:
- A: Amyloid biomarkers (Aβ42/Aβ40, amyloid PET)
- T: Tau biomarkers (p-tau181, p-tau217)
- (N): Neurodegeneration (NfL, total tau)
- I: Inflammation (sTREM2, IL-6, etc.)
- New cytokines: IL-33, IL-17, IL-23
- Exosome-derived: Inflammatory cargo in extracellular vesicles
- Proteomics: Unbiased discovery of inflammatory proteins
- Multiplex assays: Simultaneous measurement of multiple cytokines
- Blood-based: Replacing invasive CSF sampling where possible
- Standardization: Reference materials and quality control
- Anti-inflammatory treatments: NSAIDs, minocycline, colchicine trials
- Immunomodulation: Targeting specific pathways (TNF, IL-6)
- Microglial modulation: TREM2 agonists, CSF1R inhibitors